From: Viral hepatitis and HIV-associated tuberculosis: Risk factors and TB treatment outcomes in Thailand
1. Those with cure, complete, death outcomes | ||||||||
---|---|---|---|---|---|---|---|---|
Comparison groups versus non-reactive | All patients | Culture-confirmed TB | ||||||
n | AOR | 95% CI | n | AOR | 95% CI | |||
L | U | L | U | |||||
HBsAg + | 385 | 1.0 | 0.3 | 3.3 | 188 | 0.5 | 0.1 | 4.9 |
Anti-HCV + | 504 | 1.1 | 0.6 | 1.9 | 253 | 1.4 | 0.6 | 3.6 |
HBsAg and anti-HCV + | 374 | 2.1 | 0.6 | 7.6 | 185 | 4.8 | 0.5 | 42.9 |
2. Those with cure, complete, death, and default outcomes | ||||||||
Comparison groups versus non-reactive | All patients | Culture-confirmed TB | ||||||
n | AOR | 95% CI | n | AOR | 95% CI | |||
L | U | L | U | |||||
HBsAg + | 420 | 2.7 | 1.1 | 6.4 | 207 | 5.5 | 1.4 | 21.9 |
Anti-HCV + | 549 | 1.2 | 0.8 | 2.0 | 281 | 2.0 | 1.0 | 4.0 |
HBsAg and anti-HCV + | 401 | 1.4 | 0.4 | 4.7 | 198 | 1.7 | 0.3 | 11.2 |